Positive results from phase III DAPA-CKD trial of Farxiga to treat chronic kidney disease.-AstraZeneca

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (ckd) stages 2-4 and elevated urinary albumin excretion. the results were consistent in patients both with and without type-2 diabetes (t2d). ckd is a serious, progressive condition defined by decreased kidney function affecting nearly 700 million people worldwide, many of them still undiagnosed,and the most common causes are diabetes, hypertension and glomerulonephritis. the primary composite endpoint w as greater than 50% sustained decline in estimated glomerular filtration rate (egfr), onset of end-stage kidney disease (eskd) and cv or renal death. the absolute risk reduction (arr) was 5.3% over the median time in study of 2.4 years. the trial also met all secondary endpoints, including significantly reducing death from any cause by 31% (arr="2.1%," p="0.0035)" compared to placebo. the safety and tolerability of farxiga were consistent with the well-established safety profile of the medicine. in the trial, patients treated with farxiga experienced fewer serious adverse events compared to placebo (29.5% versus 33.9%, respectively). diabetic ketoacidosis was not reported in the farxiga group versus in two patients in the placebo group. detailed results from the dapa-ckd trial were presented on sunday 30 august at the esc congress 2020 – the digital experience..>